WS Investor
05 Oct 2026, 14:01
Bristol Myers Squibb Stock Falls 2.8% After Leerink Downgrade
Bristol Myers Squibb shares fell 2.8% to $59.41 after Leerink Partners downgraded the stock to Market Perform from Outperform.
Analyst David Risinger also cut the price target to $59 from $73, bringing the new target close to the stock’s current trading level and signaling a more cautious view on near-term upside potential.
The downgrade may reflect broader concerns around Bristol Myers Squibb’s growth outlook, including pressure from upcoming patent expirations on major products, the pace at which newer medicines can offset declining legacy revenue, and uncertainty around pipeline execution.
Investors are also closely watching the company’s ability to generate sufficient growth from newer oncology, cardiovascular and immunology products while managing increased competition across several key therapeutic areas.
The combination of a lower rating and sharply reduced price target appears to be weighing on the stock Monday, as the new target suggests limited expected appreciation from current levels.
Bristol Myers Squibb shares fell 2.8% to $59.41 after Leerink Partners downgraded the stock to Market Perform from Outperform.
Analyst David Risinger also cut the price target to $59 from $73, bringing the new target close to the stock’s current trading level and signaling a more cautious view on near-term upside potential.
The downgrade may reflect broader concerns around Bristol Myers Squibb’s growth outlook, including pressure from upcoming patent expirations on major products, the pace at which newer medicines can offset declining legacy revenue, and uncertainty around pipeline execution.
Investors are also closely watching the company’s ability to generate sufficient growth from newer oncology, cardiovascular and immunology products while managing increased competition across several key therapeutic areas.
The combination of a lower rating and sharply reduced price target appears to be weighing on the stock Monday, as the new target suggests limited expected appreciation from current levels.
